Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/2 study of AB8939 in refractory acute myeloid leukemia patients unfit to receive intensive chemotherapy in second and third-line

Trial Profile

A phase 1/2 study of AB8939 in refractory acute myeloid leukemia patients unfit to receive intensive chemotherapy in second and third-line

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 30 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AB-8939 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Most Recent Events

    • 30 Sep 2019 According to an AB science media release, the company expects to initiate this study in 2020.
    • 04 Jul 2019 According to an AB science media release, AB Science will host a live webcast on AB8939, focusing on the Scientific Advice procedure with EMA and resulting validated clinical development program of AB8939 in acute myeloid leukemia (AML), design of phase 1/2 studies, efficacy criteria to be met to be eligible for accelerated approval base on non-controlled phase 2 study on July 8, 2019 from 5:30 pm to 6:30 pm CET.
    • 04 Jul 2019 According to an AB science media release, the company announces today that the European Medicine Agency (EMA) has validated the clinical development program for its new compound AB8939 in acute myeloid leukemia (AML) through a Scientific Advice procedure.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top